lunes, 28 de septiembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 19, 2026

Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights

View original at finance.yahoo.com
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights Mereo BioPharma Group plc Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $41.0 million as of December 31, 2025, expected to provide runway into mid-…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Phase 3 Orbit and Cosmic studies did not achieve statistical significance on primary endpoints of fracture reduction

    60% confidence

  • Single Phase 3 trial enrolling approximately 220 AATD-LD patients will support regulatory submissions in both U.S. and Europe

    60% confidence

  • Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab in osteogenesis imperfecta are ongoing

    60% confidence

  • There are no FDA or EMA therapies approved specifically for osteogenesis imperfecta

    60% confidence

  • Partnering discussions around alvelestat in AATD-LD are continuing to advance on multiple fronts

    60% confidence

  • Existing cash and cash equivalents will enable funding of operations into mid-2027

    60% confidence

  • Setrusumab demonstrated statistically significant improvements in bone mineral density and compelling reductions in vertebral fractures

    60% confidence

  • Data from setrusumab studies may provide basis for engagement with regulatory agencies despite missing primary endpoints

    60% confidence

  • Revised financial runway into mid-2027 enables potential delivery of several key milestones during 2026

    60% confidence

  • āshibio plans to initiate a Phase 2 trial of vantictumab in osteopetrosis in the second half of 2026

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Vertical AI Agents Attract a Funding Wave Across Fintech-Adjacent Industries
A cluster of AI-native startups applying autonomous agents to narrow, operational problems — hotel front-desk staffing (Dextr AI), identity/fraud risk for financial institutions (Baselayer), insurance distribution (Napo, Connie Health, MGT Insurance) — closed seed-to-Series A rounds within days of each other in September 2026, with CB Insights running a coordinated CEO interview series to spotlight them. The pattern points to agentic AI maturing from generic chat tools into vertical, revenue-generating products, with identity verification for AI agents themselves (Baselayer) emerging as a new fintech infrastructure category responding directly to AI-driven fraud risk.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,984
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,984 hechos verificados con la fuente5,306 documentos fuente archivados
Consulta estos datos → isubstrate.com
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights — Source | Via News | es.VIA.NEWS